Dianxu Ren1,2, Oscar L Lopez3,4, Jennifer H Lingler1,4, Yvette Conley1,5. 1. School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. School of Medicine, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
OBJECTIVES: To examine the associations of APOE ε2ε4 with the development of Alzheimer's disease (AD) and mild cognitive impairment (MCI) in non-Latino whites. DESIGN: Prospective longitudinal cohort study. SETTING: Uniform Data Set from the National Alzheimer's Coordinating Center (NACC) between 2005 and August 2018 (data freeze in September 2018). PARTICIPANTS: Participants who were non-Latino white, had an APOE genotype available, first visit with dementia free for AD cohort and both dementia and MCI free for MCI cohort, and had a minimum of one follow-up visit (n = 11 871 for AD cohort, and n = 8305 for MCI cohort). MEASUREMENTS: The incidences of AD and MCI were determined based on consensus meetings at each Alzheimer's disease center. We used NACC-derived variables to define individuals experiencing incidents of AD and MCI at the initial visit as well as the follow-up visits. RESULTS: Among participants in the AD cohort (N = 11 871), ε2ε4 accounted for 2.5%, ε2ε2 accounted for 0.4%, ε2ε3 accounted for 11.0%, ε4ε4 accounted for 4.4%, ε3ε4 accounted for 27.3%, and ε3ε3 accounted for 54.4%. Over an average of 4.6 years follow-up, 1857 (15.6%) developed AD dementia, with the range from 6.0% to 35.2% across the six groups. Compared to ε3ε3 carriers, ε2ε4 carriers exhibited an increased risk of incident AD (18.4% vs 11.7%; adjusted hazard ratio [aHR] = 1.74; 95% confidence interval [CI] = 1.32-2.30; P < .0001). Among participants in the MCI cohort (N = 8305), the average follow-up was 4.7 years, and 1912 (23.0%) developed MCI, with the range from 20.4% to 33.9% across the six groups. Compared to ε3ε3 carriers, ε2ε4 carriers exhibited an increased risk of incident MCI (27.5% vs 21.5%; aHR = 1.52; 95% CI = 1.15-1.99; P = .003). CONCLUSIONS: The APOE ε2ε4 genotype is associated with the increased risk of AD and MCI in non-Latino whites. J Am Geriatr Soc 68:1044-1049, 2020.
OBJECTIVES: To examine the associations of APOE ε2ε4 with the development of Alzheimer's disease (AD) and mild cognitive impairment (MCI) in non-Latino whites. DESIGN: Prospective longitudinal cohort study. SETTING: Uniform Data Set from the National Alzheimer's Coordinating Center (NACC) between 2005 and August 2018 (data freeze in September 2018). PARTICIPANTS: Participants who were non-Latino white, had an APOE genotype available, first visit with dementia free for AD cohort and both dementia and MCI free for MCI cohort, and had a minimum of one follow-up visit (n = 11 871 for AD cohort, and n = 8305 for MCI cohort). MEASUREMENTS: The incidences of AD and MCI were determined based on consensus meetings at each Alzheimer's disease center. We used NACC-derived variables to define individuals experiencing incidents of AD and MCI at the initial visit as well as the follow-up visits. RESULTS: Among participants in the AD cohort (N = 11 871), ε2ε4 accounted for 2.5%, ε2ε2 accounted for 0.4%, ε2ε3 accounted for 11.0%, ε4ε4 accounted for 4.4%, ε3ε4 accounted for 27.3%, and ε3ε3 accounted for 54.4%. Over an average of 4.6 years follow-up, 1857 (15.6%) developed AD dementia, with the range from 6.0% to 35.2% across the six groups. Compared to ε3ε3 carriers, ε2ε4 carriers exhibited an increased risk of incident AD (18.4% vs 11.7%; adjusted hazard ratio [aHR] = 1.74; 95% confidence interval [CI] = 1.32-2.30; P < .0001). Among participants in the MCI cohort (N = 8305), the average follow-up was 4.7 years, and 1912 (23.0%) developed MCI, with the range from 20.4% to 33.9% across the six groups. Compared to ε3ε3 carriers, ε2ε4 carriers exhibited an increased risk of incident MCI (27.5% vs 21.5%; aHR = 1.52; 95% CI = 1.15-1.99; P = .003). CONCLUSIONS: The APOE ε2ε4 genotype is associated with the increased risk of AD and MCI in non-Latino whites. J Am Geriatr Soc 68:1044-1049, 2020.
Authors: E Genin; D Hannequin; D Wallon; K Sleegers; M Hiltunen; O Combarros; M J Bullido; S Engelborghs; P De Deyn; C Berr; F Pasquier; B Dubois; G Tognoni; N Fiévet; N Brouwers; K Bettens; B Arosio; E Coto; M Del Zompo; I Mateo; J Epelbaum; A Frank-Garcia; S Helisalmi; E Porcellini; A Pilotto; P Forti; R Ferri; E Scarpini; G Siciliano; V Solfrizzi; S Sorbi; G Spalletta; F Valdivieso; S Vepsäläinen; V Alvarez; P Bosco; M Mancuso; F Panza; B Nacmias; P Bossù; O Hanon; P Piccardi; G Annoni; D Seripa; D Galimberti; F Licastro; H Soininen; J-F Dartigues; M I Kamboh; C Van Broeckhoven; J C Lambert; P Amouyel; D Campion Journal: Mol Psychiatry Date: 2011-05-10 Impact factor: 15.992
Authors: H Houlden; R Crook; H Backhovens; G Prihar; M Baker; M Hutton; M Rossor; J J Martin; C Van Broeckhoven; J Hardy Journal: Am J Med Genet Date: 1998-02-07
Authors: M C Chartier-Harlin; M Parfitt; S Legrain; J Pérez-Tur; T Brousseau; A Evans; C Berr; O Vidal; P Roques; V Gourlet Journal: Hum Mol Genet Date: 1994-04 Impact factor: 6.150
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Shimaa A Heikal; Mohamed Salama; Yuliya Richard; Ahmed A Moustafa; Brian Lawlor Journal: Front Aging Neurosci Date: 2022-02-07 Impact factor: 5.750